322 related articles for article (PubMed ID: 35032137)
1. Assessment of Anti-Xa activity in patients receiving concomitant apixaban with strong p-glycoprotein inhibitors and statins.
Milner E; Ainsworth M; Gleaton M; Bookstaver D
J Clin Pharm Ther; 2022 May; 47(5):668-675. PubMed ID: 35032137
[TBL] [Abstract][Full Text] [Related]
2. A Real-World Matched Cohort Study of the Effect of Concomitant Amiodarone or Diltiazem Administration on Apixaban Peak and Trough Concentrations.
Bookstaver DA; Ainsworth M; Gleaton M; Milner E
Am J Cardiovasc Drugs; 2023 Jan; 23(1):59-66. PubMed ID: 36316614
[TBL] [Abstract][Full Text] [Related]
3. Co-administration of statins with cytochrome P450 3A4 inhibitors in a UK primary care population.
Bakhai A; Rigney U; Hollis S; Emmas C
Pharmacoepidemiol Drug Saf; 2012 May; 21(5):485-93. PubMed ID: 22237927
[TBL] [Abstract][Full Text] [Related]
4. Risk management of simvastatin or atorvastatin interactions with CYP3A4 inhibitors.
Molden E; Skovlund E; Braathen P
Drug Saf; 2008; 31(7):587-96. PubMed ID: 18558792
[TBL] [Abstract][Full Text] [Related]
5. Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor.
Frost CE; Byon W; Song Y; Wang J; Schuster AE; Boyd RA; Zhang D; Yu Z; Dias C; Shenker A; LaCreta F
Br J Clin Pharmacol; 2015 May; 79(5):838-46. PubMed ID: 25377242
[TBL] [Abstract][Full Text] [Related]
6. Does atorvastatin therapy change the anti-Xa activity in xabans-treated patients with atrial fibrillation?
Škorňová I; Samoš M; Bolek T; Stančiaková L; Vádelová Ľ; Galajda P; Staško J; Kubisz P; Mokáň M
Pharmacol Res Perspect; 2021 May; 9(3):e00730. PubMed ID: 33984191
[TBL] [Abstract][Full Text] [Related]
7. Results of a safety initiative for patients on concomitant amiodarone and simvastatin therapy in a Veterans Affairs medical center.
Karimi S; Hough A; Beckey C; Parra D
J Manag Care Pharm; 2010 Sep; 16(7):472-81. PubMed ID: 20726676
[TBL] [Abstract][Full Text] [Related]
8. HMG-CoA Reductase Inhibitors (Statins) and their Drug Interactions Involving CYP Enzymes, P-glycoprotein and OATP Transporters-An Overview.
Balasubramanian R; Maideen NMP
Curr Drug Metab; 2021; 22(5):328-341. PubMed ID: 33459228
[TBL] [Abstract][Full Text] [Related]
9. Co-medication of statins and CYP3A4 inhibitors before and after introduction of new reimbursement policy.
Devold HM; Molden E; Skurtveit S; Furu K
Br J Clin Pharmacol; 2009 Feb; 67(2):234-41. PubMed ID: 19220274
[TBL] [Abstract][Full Text] [Related]
10. Influence of statin treatment on platelet inhibition by clopidogrel - a randomized comparison of rosuvastatin, atorvastatin and simvastatin co-treatment.
Malmström RE; Ostergren J; Jørgensen L; Hjemdahl P;
J Intern Med; 2009 Nov; 266(5):457-66. PubMed ID: 19549094
[TBL] [Abstract][Full Text] [Related]
11. Effects of simvastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, after oral and intravenous administration in rats: possible role of P-glycoprotein and CYP3A4 inhibition by simvastatin.
Choi DH; Choi JS; Li C; Choi JS
Pharmacol Rep; 2011; 63(6):1574-82. PubMed ID: 22358108
[TBL] [Abstract][Full Text] [Related]
12. Relationship between genetic polymorphism of drug transporters and the efficacy of Rosuvastatin, atorvastatin and simvastatin in patients with hyperlipidemia.
Sivkov A; Chernus N; Gorenkov R; Sivkov S; Sivkova S; Savina T
Lipids Health Dis; 2021 Nov; 20(1):157. PubMed ID: 34749751
[TBL] [Abstract][Full Text] [Related]
13. Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy.
Becker ML; Visser LE; van Schaik RH; Hofman A; Uitterlinden AG; Stricker BH
Pharmacoepidemiol Drug Saf; 2010 Jan; 19(1):75-81. PubMed ID: 19802823
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic drug-drug interactions between 1,4-dihydropyridine calcium channel blockers and statins: factors determining interaction strength and relevant clinical risk management.
Zhou YT; Yu LS; Zeng S; Huang YW; Xu HM; Zhou Q
Ther Clin Risk Manag; 2014; 10():17-26. PubMed ID: 24379677
[TBL] [Abstract][Full Text] [Related]
15. Frequency and clinical relevance of drug interactions with lovastatin and simvastatin: an observational database study.
Tirkkonen T; Ryynänen A; Vahlberg T; Irjala K; Klaukka T; Huupponen R; Laine K
Drug Saf; 2008; 31(3):231-40. PubMed ID: 18302447
[TBL] [Abstract][Full Text] [Related]
16. Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.
Foody JM; Toth PP; Tomassini JE; Sajjan S; Ramey DR; Neff D; Tershakovec AM; Hu H; Tunceli K
Vasc Health Risk Manag; 2013; 9():719-27. PubMed ID: 24265554
[TBL] [Abstract][Full Text] [Related]
17. Risks of Adverse Events Following Coprescription of Statins and Calcium Channel Blockers: A Nationwide Population-Based Study.
Wang YC; Hsieh TC; Chou CL; Wu JL; Fang TC
Medicine (Baltimore); 2016 Jan; 95(2):e2487. PubMed ID: 26765458
[TBL] [Abstract][Full Text] [Related]
18. A population-based analysis of the risk of drug interaction between clarithromycin and statins for hospitalisation or death.
Mesgarpour B; Gouya G; Herkner H; Reichardt B; Wolzt M
Lipids Health Dis; 2015 Oct; 14():131. PubMed ID: 26497728
[TBL] [Abstract][Full Text] [Related]
19. Physiologically-Based Pharmacokinetic Modeling for the Prediction of a Drug-Drug Interaction of Combined Effects on P-glycoprotein and Cytochrome P450 3A.
Otsuka Y; Choules MP; Bonate PL; Komatsu K
CPT Pharmacometrics Syst Pharmacol; 2020 Nov; 9(11):659-669. PubMed ID: 33030266
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design.
Polli JW; Hussey E; Bush M; Generaux G; Smith G; Collins D; McMullen S; Turner N; Nunez DJ
Xenobiotica; 2013 Jun; 43(6):498-508. PubMed ID: 23256625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]